Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

Neurizon confirms positive results for prospective ALS treatment

June 23, 2025 Research and Development Neurizon Therapeutics, Neurology, amyotrophic lateral sclerosis, blood-brain barrier, clinical data, neurodegenerative diseases

Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain …
News
blood-1813410_960_720

Novo Nordisk presents promising findings for haemophilia treatment

June 23, 2025 Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval

Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …
News

NICE recommends spevigo for rare and severe psoriasis flares

June 20, 2025 Medical Communications, Research and Development Dermatology, NHS, National Institute for Health and Care Excellence, generalised pustular psoriasis

The National Institute for Health and Care Excellence (NICE) has recommended Spevigo (spesolimab) for the treatment of generalised pustular psoriasis …
News

First UK patient treated with CSL Behring’s gene therapy for Haemophilia B

June 20, 2025 Research and Development CSL Behring, Haematology, NHS England, cell therapy, gene therapy, haemophilia B, prophylactic infusions

CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene dezaparvovec) through the NHS, marking …
News

Eyestem completes phase 1 trial of retinal cell therapy with promising vision gains

June 20, 2025 Research and Development Eyestem Research, Opthalmology, cell therapy, clinical trial, dry age-related macular degeneration, geographic atrophy

Eyestem Research has announced the successful completion of its phase 1 trial evaluating Eyecyte-RPE, an investigational cell therapy for geographic …
News
money-2180330_960_720

Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology

June 20, 2025 Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer

Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research …
News

Celltrion opens new UK headquarters in Uxbridge to drive long-term growth

June 19, 2025 Research and Development Corporate, Pharmacy, biosimilar medicines, celltrion

Celltrion, focused on the development of biosimilar medicines, has officially opened its new UK headquarters in the Charter Building, Uxbridge, …
News
handshake

KFSHRC and Germfree to launch first modular ATMP manufacturing campus in Saudi Arabia

June 19, 2025 Medical Communications, Research and Development Advanced Therapy Medicinal Product manufacturing, BIO 2025, Corporate, King Faisal Specialist Hospital & Research Centre, Saudi Arabia, biotechnology development, cell therapies, gene therapies

King Faisal Specialist Hospital & Research Centre (KFSHRC) has announced a landmark partnership with Germfree Laboratories to develop Saudi Arabia’s …
News
AstraZeneca_drug_discovery

Bristol Myers Squibb to present positive new data on lymphoma treatment

June 18, 2025 Medical Communications, Research and Development Bristol Myers Squibbs, CAR T-cell therapy, International Conference on Malignant Lymphoma, Oncology, relapsed or refractory marginal zone lymphoma

Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) …
News
lab

Captain T Cell joins Bayer Co.Lab Berlin to accelerate TCR therapies

June 18, 2025 Analytical & Laboratory Services, Business Services, Research and Development Bayer Co.Lab, Bayer Co.Lab Berlin, Captain T Cell, Corporate, T-cell receptor therapy, laboratory services

Captain T Cell, a biotech company developing next-generation T-cell receptor (TCR)-based therapies for solid tumours, has announced its selection for …
News
money_pills_2

EVerZom receives €3m funding from French government to industrialise exosome technology

June 18, 2025 Research and Development BpiFfrance, Corporate, Crohn’s disease, EVerZom, France 2030, French government, age-related disorders, exosome therapy, neurodegenerative disease

EVerZom, a French biopharma company focused on exosome-based therapies, has announced it has received €3m in funding as part of …
News

Samra Turajlić appointed director of Cancer Research UK Manchester Institute

June 18, 2025 Medical Communications, Research and Development Cancer Research UK, Cancer Research UK Manchester Institute, Oncology, The Royal Marsden NHS Foundation Trust, University of Manchester, cancer research

Cancer Research UK has announced the appointment of Samra Turajlić as the new director of the Cancer Research UK Manchester …
Appointment

Biotium launches new DNA gel analysis technology

June 17, 2025 Business Services, Research and Development Biotium, Corporate, DNA gel analysis, DNAzure blue nucleic acid gel stain, glo-plate white photoactivation device, life sciences reagents

Biotium has announced the launch of its new glo-plate white photoactivation device, a compact LED-powered light box designed to support …
News
Bowel cancer screening image

Scientists discover reason for resistance to bowel cancer treatment

June 17, 2025 Research and Development Cancer Research UK, Oncology, The Institute of Cancer Research, bowel cancer, drug resistance

Scientists funded by Cancer Research UK have demonstrated what may cause some treatments to stop working in people living with …
News

Johnson & Johnson presents promising data on leukaemia treatment

June 16, 2025 Medical Communications, Research and Development European Hematology Association, Janssen-Cilag, Johnson & Johnson, Oncology, chronic lymphocytic leukaemia, clinical trial

Janssen-Cilag, a Johnson & Johnson company, has announced results from a matching-adjusted indirect comparison presented at this year’s European Hematology …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026